Please assess the completion status of the following clinical trial:

Trial Title: Improving Medication Adherence in Post-ACS Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Medical eligibility:~   1. Patient presenting for staged intervention with positive cardiac history OR~  2. Patient with stable CAD who received cardiac admission but does not report chest pain. OR~  3. Patient with stable CAD who has had a cardiac admission in the past.~2. Patient is non-adherent to prescribed medication.~The following exclusion criteria have been set for either safety concerns or concerns that patients will not be able to complete the protocol:~1. inability to communicate in English or Spanish~2. unwilling to be randomized or to have aspirin in a separate bottle if they use a pill box~3. unavailability for the 1 month period of the study (including being unavailable by phone and/or traveling out of the country)~4. medically unable to receive aspirin (e.g. allergy, contra-indicated, etc)~5. deemed unable to comply with the protocol (either self selected or by indicating during screening that s/he could not complete all requested tasks). This includes patients with a level of cognitive impairment indicative of dementia, and patients with current alcohol or substance abuse.~6. deemed to need immediate psychiatric assessment (e.g., must be hospitalized, or have some other psychiatric intervention conducted within 72 hours).~7. active psychosis, bipolar disorder, or any overt personality disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: NO_INTERVENTION): Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin.~Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians.
- B (Type: EXPERIMENTAL): Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.

Based on this trial design, predict the completion outcome and termination type (if applicable).